CytomX Therapeutics stock analysis
CytomX Therapeutics (6C1) Stock Price & Analysis
6C1 Stock Chart & Stats
- Day’s Range
- EUR 1.72 - EUR 1.72
- 52-Week Range
- EUR 1.72 - EUR 6.97
- Previous Close
- EUR 1.92
- Volume
- N/A
- Average Volume (3M)
- 50
- Market Cap
- EUR 388.99M
- Enterprise Value
- EUR 251.46M
- Total Cash (Recent Filing)
- EUR 347.98M
- Total Debt (Recent Filing)
- EUR 4.39M
- Price to Earnings (P/E)
- ―
- Beta
- 1.44
- Next Earnings
- Feb 24, 2027 (Est.)
- EPS Estimate
- -0.08
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Differentiated Oncology Pipeline
Varseta-M’s potentially differentiated EpCAM-targeting design and Probody platform provide a focused basis for clinical and commercial positioning. Advancement toward a possible registrational study could create a durable value driver if the program confirms its early efficacy and safety advantages.
Extended Liquidity
A projected cash runway into the second half of 2028 gives CytomX time to fund Varseta-M registrational preparation, combination studies, and broader tumor cohorts. This reduces near-term financing pressure and supports continued development without relying immediately on a favorable capital market.
Improving Treatment Tolerability
The lower Grade 3 diarrhea rate in dose-optimization cohorts suggests that dosing and prophylaxis changes may improve Varseta-M’s therapeutic window. If sustained with longer follow-up, better tolerability could support dose intensity, broader use, and progress toward registrational development.
Bears Say
Collaboration Revenue Decline
The Astellas collaboration conclusion materially reduced reported revenue, highlighting CytomX’s dependence on collaboration and licensing economics while it remains clinical-stage. Lower partnership income can weaken internal funding capacity and increase reliance on milestone timing or future financing.
Persistent Cash Burn
Sustained negative operating and free cash flow show that CytomX is not currently self-funding its development strategy. Continued cash consumption will eventually require milestone receipts, partnership funding, or capital raising, creating ongoing financial pressure despite the currently projected runway.
Gastrointestinal Safety Risk
Persistent gastrointestinal toxicity remains a material development risk because it may limit dose intensity, complicate combination regimens, and affect patient treatment continuity. The issue is particularly important as CytomX expands Varseta-M into earlier-line and multi-drug studies.
6C1 FAQ
What was CytomX Therapeutics’s price range in the past 12 months?
What is CytomX Therapeutics’s market cap?
When is CytomX Therapeutics’s upcoming earnings report date?
How were CytomX Therapeutics’s earnings last quarter?
Is CytomX Therapeutics overvalued?
Does CytomX Therapeutics pay dividends?
What is CytomX Therapeutics’s EPS estimate?
How many shares outstanding does CytomX Therapeutics have?
What happened to CytomX Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of CytomX Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
CytomX Therapeutics Stock Smart Score
Company Description
CytomX Therapeutics
CytomX Therapeutics, Inc. is a United States-based biopharmaceutical company primarily focused on creating treatments for cancer. The company utilizes its proprietary Probody technology platform to engineer targeted antibody therapeutics for oncological applications. Its robust clinical pipeline includes several notable drug candidates. CX-2009, an antibody-drug conjugate (ADC) designed to target CD166, is currently in Phase II clinical trials for treating breast cancer. Another investigational therapy, CX-2029, has also reached Phase II trials, where it is being evaluated for various cancers such as squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma. Additionally, CytomX is progressing two CTLA-4 Probody therapeutics: BMS-986249, which is undergoing Phase I/II clinical trials for metastatic melanoma, and BMS-986288, in Phase I trials for solid tumors. Beyond these, the company is developing CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, and CX-904, a conditionally activated epidermal growth factor receptor, both aimed at addressing solid tumor conditions. CytomX has forged strategic partnerships with leading pharmaceutical firms, including AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc., to collaboratively advance its Probody therapeutics. The company was founded in 2008 and its main office is located in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sean A. McCarthy
- Employees
- 69
- Website
- www.cytomx.com
- Address
- 151 Oyster Point Boulevard, South San Francisco, CA, 94080, US
CytomX Therapeutics (6C1) Earnings & Revenues
6C1 Earnings Call
Earnings Call SentimentPositive
The call was predominantly positive, with management highlighting progress toward a potential first registrational study for Varseta-M in the first half of 2027, encouraging progression-free survival, improved Grade 3 diarrhea results in dose optimization, expanding combination and pan-tumor programs, continued CX-801 enrollment, and cash runway into the second half of 2028. These positives were tempered by lower revenue following the Astellas collaboration conclusion, higher operating expenses, ongoing gastrointestinal toxicity management, and the delay of the monotherapy update to January.
View all DE:6C1 earnings summaries6C1 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 3 | 14 |
| Technical Analysis | 5 | 3 | 2 |
| Moving Averages | 0 | 0 | 12 |
